Sun Pharma’s board has approved an investment of ₹3,000 crores for a greenfield formulations manufacturing facility in Madhya Pradesh. This strategic move aims to expand the company’s manufacturing capabilities and cater to growing demand. The new facility will bolster Sun Pharma’s position in the pharmaceutical sector and contribute to the company’s long-term growth strategy. The board’s decision reflects confidence in the future of the pharmaceutical industry.
Investment in New Manufacturing Facility
Sun Pharma Laboratories Limited, a wholly-owned subsidiary of Sun Pharmaceutical Industries, has received board approval for a significant investment. The company plans to invest ₹3,000 crores in a new greenfield formulations manufacturing facility located in Madhya Pradesh. This decision was formally announced on December 2, 2025.
Strategic Rationale
The investment in a new manufacturing facility aligns with Sun Pharma’s strategic objectives. The new facility is intended to increase the company’s manufacturing capacity and strengthen its ability to meet growing demands for its pharmaceutical products. This expansion will enhance Sun Pharma’s operational capabilities and reinforce its commitment to the pharmaceutical sector.
Source: BSE